U.S. Hospitality Stock News

NYSE:JBTM
NYSE:JBTMMachinery

Is JBT Marel (JBTM) Still Attractive After Recent Share Price Strength?

If you are wondering whether JBT Marel at US$156.04 is still a sensible entry point or more of a hold, the next sections will walk through what the current price may be implying about value. The stock has recorded returns of 3.6% over the past week, 1.5% over the last month, 3.6% year to date and 28.5% over the past year, with a 55.0% return over three years and 25.8% over five years. These figures can affect how investors think about both upside potential and downside risk. Recent attention...
NYSE:NABL
NYSE:NABLSoftware

Is N-able (NABL) Offering An Opportunity After Its 19.7% One Year Share Price Decline

If you are wondering whether N-able's share price around US$7.31 actually reflects its underlying worth, you are not alone. This article is built to help you size that up clearly. Over the past week the stock is roughly flat at a 0.1% return, but that sits against a 4.2% decline over 30 days and a 19.7% decline over the past year, which can change how investors view both its potential and its risks. Recent coverage has focused on how N-able is positioned within the broader software and IT...
NYSE:RPC
NYSE:RPCCapital Markets

Is P10 (PX) Pricing Justified After Three-Year Share Price Decline?

If you have been wondering whether P10 is priced attractively right now, you are not alone. Many investors are asking the same question about what they are really paying for with this stock. P10 shares last closed at US$10.33, with recent returns of 4.4% over the past week, 1.2% over the past month, 4.4% year to date, and a 17.6% decline over the past year and 7.6% decline over three years. Recent market attention on P10 has been shaped by ongoing discussion around its role in the...
NasdaqGM:IMRX
NasdaqGM:IMRXBiotechs

Why Immuneering (IMRX) Is Down 29.7% After Phase 2a Pancreatic Data Versus Historical Benchmarks And Phase 3 Plan

Immuneering Corporation recently reported updated Phase 2a data showing encouraging overall survival, response, and safety outcomes for its atebimetinib plus modified gemcitabine/nab-paclitaxel regimen in previously untreated pancreatic cancer patients, and confirmed plans to begin a pivotal Phase 3 trial in mid-2026. A key nuance is that the reported survival benefit is based on comparisons to historical MPACT trial benchmarks rather than a head-to-head control arm, which may influence how...
NYSE:BLX
NYSE:BLXDiversified Financial

Is Banco Latinoamericano De Comercio Exterior (BLX) Still Priced Attractively After Its Recent Run?

If you are wondering whether Banco Latinoamericano de Comercio Exterior S. A is still attractively priced after its recent run, this article will walk through what the current share price might imply about value. The stock closed at US$43.45, with returns of 26.7% over the past year, even though the last 7 days and 30 days saw returns of a 0.8% decline and a 3.5% decline respectively. Recent interest around BLX has largely centered on its role as a specialist trade finance bank for Latin...
NYSE:TFX
NYSE:TFXMedical Equipment

Teleflex (TFX) Valuation After 2025 Outlook Cut And CEO Change

What triggered the latest Teleflex stock reaction Teleflex (TFX) shares moved after the company cut its 2025 revenue outlook and announced leadership changes, including the departure of long standing CEO Liam Kelly and the appointment of interim CEO Stuart Randle. See our latest analysis for Teleflex. Those guidance cuts and leadership changes came after a weaker patch, with a 30 day share price return of 11.35% and a 1 year total shareholder return decline of 34.67%, showing momentum has...
NasdaqCM:LQDA
NasdaqCM:LQDAPharmaceuticals

Is It Too Late To Reassess Liquidia (LQDA) After Its Sharp Share Price Surge?

If you are wondering whether Liquidia's share price still offers value after a strong run, the starting point is understanding how its current market price lines up with different ways of estimating worth. Liquidia's stock closed at US$35.86, with returns of 14.2% over the past week, 9.7% over the past month and 14.2% year to date, while the 1 year return sits at 194.2% and the 3 year return is very large. Recent attention on Liquidia has centered on its position in pharmaceuticals and...
NasdaqGS:PCRX
NasdaqGS:PCRXPharmaceuticals

Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure

What triggered the latest move in Pacira BioSciences? Pacira BioSciences (PCRX) has drawn attention after reporting record EXPAREL sales with 7% volume growth in what it called its strongest fourth quarter in three years, along with a completed fourth quarter share repurchase and fresh activist pressure on the board. See our latest analysis for Pacira BioSciences. Despite record EXPAREL sales and a completed buyback that retired 13.28% of shares under the May 2025 program, Pacira BioSciences’...
NasdaqGS:QURE
NasdaqGS:QUREBiotechs

Is It Time To Reassess uniQure (QURE) After 83% One Year Share Price Gain?

If you are wondering whether uniQure's share price lines up with its underlying value, this article walks through the key numbers so you can judge for yourself. Over the past year, uniQure's stock has returned 82.8%, with shorter term moves of 8.3% over 7 days and 25.7% over 30 days from a last close of US$25.32. These shifts can affect how investors think about both upside and risk. Recent news around uniQure has focused on its gene therapy pipeline and partnerships, which helps explain why...
NYSE:EIX
NYSE:EIXElectric Utilities

Is Edison International (EIX) Pricing Reflect Grid Reliability And Wildfire Risk Concerns?

If you are wondering whether Edison International is offering fair value right now, it helps to step back and line up what the recent share performance and fundamentals are actually telling you. The stock last closed at US$60.99, with returns of 0.1% over 7 days, 6.1% over 30 days, 0.1% year to date, 0.3% decline over 1 year, 3.5% over 3 years, and 24.7% over 5 years. Taken together, these figures give a mixed picture of how the market has been pricing the company over different time...
NYSE:AAT
NYSE:AATREITs

Is There Now An Opportunity In American Assets Trust (AAT) After Mixed Long Term Returns?

If you are wondering whether American Assets Trust is simply out of favor or quietly offering value, starting with the recent share performance can help frame the opportunity and the risks. The stock last closed at US$18.84, with returns of 0.3% over the past week, a 1.1% decline over 30 days, 0.3% year to date, and longer term returns of 14.5% decline over 1 year, 18.0% decline over 3 years, and 15.8% decline over 5 years. These mixed returns sit against a real estate backdrop where...
NasdaqGS:JKHY
NasdaqGS:JKHYDiversified Financial

Is It Too Late To Consider Jack Henry & Associates (JKHY) After Recent Share Price Strength?

If you are wondering whether Jack Henry & Associates is priced fairly or not, this is where we start connecting the share price to what you are actually paying for. The stock last closed at US$189.16, with returns of 6.1% over the past week, 1.1% over the last month, 6.1% year to date, 11.5% over 1 year, 8.3% over 3 years and 30.2% over 5 years. This gives some context for how the market has been reassessing the company. Recent coverage has focused on Jack Henry & Associates as a key player...
NYSE:SHCO
NYSE:SHCOHospitality

A Look At Soho House & Co (SHCO) Valuation After Mixed Short And Long Term Returns

Soho House & Co (SHCO) has recently drawn investor attention after a period of mixed share performance, with the stock showing a small positive 1 year total return alongside negative moves over the past week, month and past 3 months. See our latest analysis for Soho House & Co. The recent 1 day share price return of 2.59% decline, alongside weaker 7 day and 30 day share price returns, suggests fading short term momentum, even as the 3 year total shareholder return of 48.78% points to a...
NYSE:WH
NYSE:WHHospitality

Is Wyndham Hotels & Resorts (WH) Attractive After Recent Share Price Weakness?

If you are wondering whether Wyndham Hotels & Resorts is attractively priced right now, it helps to first step back and see how the stock has been behaving. The share price closed at US$81.11, with recent returns of 7.8% over 7 days, 7.2% over 30 days, 7.8% year to date and a 17.7% decline over 1 year, alongside gains of 16.7% over 3 years and 45.6% over 5 years. These mixed returns sit against a backdrop of ongoing industry news around travel demand, brand consolidation and competition...